Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells
Zhe Chang, Zhongkui Li, Xiaoyang Wang, Ya'an Kang, Yuhui Yuan, Jiangong Niu, Huamin Wang, Deyali Chatterjee, Jason B. Fleming, Min Li, James L. Abbruzzese, and Paul J. Chiao

SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival
Mohamed Hassanein, Megan D. Hoeksema, Masakazu Shiota, Jun Qian, Bradford K. Harris, Heidi Chen, Jonathan E. Clark, William E. Alborn, Rosana Eisenberg, and Pierre P. Massion

Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer
Heather Ann Brauer, Liza Makowski, Katherine A. Hoadley, Patricia Casbas-Hernandez, Lindsay J. Lang, Erick Román-Pérez, Monica D’Arcy, Alex J. Freermerman, Charles M. Perou, and Melissa A. Troester

Molecular Pathways: Targeted α-Particle Radiation Therapy
Kwamena E. Baidoo, Kwon Yong, and Martin W. Brechbiel

Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer
Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, and Andrew M. Lowy

Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Joan T. Garrett, Cammie R. Sutton, María Gabriela Kubá, Rebecca S. Cook, and Carlos L. Arteaga
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal

Giuseppe Floris, Agnieszka Wozniak, Raf Sciot, Haifu Li, Lori Friedman, Thomas Van Looy, Jasmien Wellens, Peter Vermaelen, Christophe M. Derose, Jonathan A. Fletcher, Maria Debie-Jechtj, and Patrick Schöffski

Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex

Hacer Guvenc, Marat S. Pavlyukov, Kaushal Joshi, Habibe Kurt, Yeshavanth K. Banasavadi-Siddegowda, Ping Mao, Christopher Hong, Ryosuke Yamada, Chang-Hyuk Kwon, Depak Bhasin, Somsundaram Chettiar, Gaspar Kitange, In-Hee Park, Jann N. Sarkaria, Chenglong Li, Mihail I. Shakhparonov, and Ichiro Nakano

Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms


See commentary, p. 511

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents


Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production

Kotaro Saga, Katsuto Tami, Takehiko Yamazaki, and Yasufumi Kaneda

Antitumor Activity of Cell-Permeable RUNX3 Protein in Gastric Cancer Cells

Junghee Lim, Tam Duong, Nga Do, Phuong Do, Jaetaek Kim, Hyunchul Kim, Wael El-Rifai, H. Earl Ruley, and Daewoong Jo

Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing

Fiamma Buiti, Talita Felicioni, Maela Del Grammastro, Giampalpa Filice, Alessia Di Lorio, Sara Malatesta, Patrizia Viola, Irene Cen, Tommaso D’Antuono, Roberta Zappacosta, Sandra Rosini, Franco Cuccurullo, and Antonio Marchetti

Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression

Éric Lévesque, Shi-Pin Huang, Étienne Audet-Walsh, Louis Lacombe, Bo-Ying Bao, Yves Fradet, Isabelle Laverdière, Mélanie Rouleau, Chao-Yuan Huang, Chia-Cheng Yu, Patrick Caron, and Chantal Guimellette

Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and β-Catenin Predicts Distant Metastasis of Colon Cancer

Helge Siemens, Jens Neumann, Rene Jackstadt, Ulrich Mansmann, David Horst, Thomas Kirchner, and Heiko Hermeking

γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)


Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma

Kimberley Jones, Frank Vari, Colm Keane, Pauline Crooks, Jamie P. Nourse, Louise A. Seymour, David Gottlieb, David Ritchie, Devinder Gill, and Maher K. Gandhi
ABOUT THE COVER

Cytology specimens may represent the only available material for molecular diagnosis in non–small cell lung cancer patients. When the number of neoplastic cells in these samples is very low in a large excess of nonneoplastic cells, the specimen is usually judged inadequate for mutation analysis with conventional methods. The cover figure shows a cytological smear obtained from a bronchoalveolar lavage with a limited number of tumor cells. Next-generation sequencing can greatly improve the detection of mutations in these cases. For details, see the article by Buttitta and colleagues on page 691 of this issue.
Clinical Cancer Research

19 (3)


Updated version  Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/19/3

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.